0001104659-06-077018.txt : 20061121 0001104659-06-077018.hdr.sgml : 20061121 20061121171416 ACCESSION NUMBER: 0001104659-06-077018 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20061117 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20061121 DATE AS OF CHANGE: 20061121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARQULE INC CENTRAL INDEX KEY: 0001019695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043221586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21429 FILM NUMBER: 061233591 BUSINESS ADDRESS: STREET 1: 19 PRESIDENTIAL WAY CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-994-0300 MAIL ADDRESS: STREET 1: 19 PRESIDENTIAL WAY CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 a06-24469_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported November 17, 2006

ARQULE, INC.
(Exact Name of Issuer as Specified in Charter)

Delaware	000-21429	04-3221586
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification No.)

	19 Presidential Way Woburn, MA
	(Address of principal executive offices)

01801
(Zip code)

(781) 994-0300
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))

Section 5 — Corporate Governance and Management

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(b) On November 17, 2006, Tuan Ha-Ngoc resigned as a member of the Board of Directors of ArQule, Inc. (the “Registrant”). Mr. Ha-Ngoc is President and Chief Executive Officer of AVEO Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of novel cancer therapeutics.

A press release dated November 21, 2006 announcing Mr. Ha Ngoc’s departure is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Section 9 —Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Text of Press Release dated November 21, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



		ARQULE, INC.
		(Registrant)

		/s/ Peter S. Lawrence
		Peter S. Lawrence
		Executive Vice President,
		Chief Business Officer and General Counsel

Date: November 21, 2006

EX-99.1 2 a06-24469_1ex99d1.htm EX-99

Exhibit 99.1

William B. Boni
VP, Investor Relations/
Corp. Communications
(781) 994-0300
www.ArQule.com

FOR IMMEDIATE RELEASE:

ARQULE ANNOUNCES DEPARTURE OF BOARD MEMBER

Woburn, MA, November 21, 2006 — ArQule, Inc. (Nasdaq: ARQL) today announced the resignation of Tuan Ha-Ngoc, a director of the company, effective November 17, 2006. Mr. Ha-Ngoc is president and chief executive officer of AVEO Pharmaceuticals Inc. Because both ArQule and AVEO are engaged in oncology-focused drug discovery and development, Mr. Ha-Ngoc decided that it was an appropriate time for him to step down from the board of ArQule.

“Tuan Ha-Ngoc’s distinguished tenure on the board of ArQule has coincided with the company’s transition to a clinical-stage research and development-based company from a chemical services business,” said Stephen A. Hill, president and chief executive officer of ArQule. “He leaves the board of ArQule with my sincere thanks and with the best wishes of the entire board and management of our company.”

About ArQule

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are designed to affect key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms. The first of these, Activated Checkpoint TherapySM (ACT), is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F1 pathway, is partnered with Roche. ArQule’s second cancer platform, Cancer Survival Protein modulation, has generated a clinical-stage product designed to inhibit a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. For more information, please visit www.arqule.com.

###